Psoriasis skin disease. Psoriasis vulgaris
Conditions
Interventions
Intervention 1: The first group will receive the standard treatment in addition to the topical form of atorvastatin made by the researcher, and the second group will receive the standard treatment in
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: over 18 years old Psoriasis patients referred to the skin outpatient clinic of Shahada Mehrab Hospital
Exclusion criteria
Exclusion criteria: pregnancy or lactation Patients suffering from several skin diseases at the same time Patients using non-steroidal anti-inflammatory drugs daily or more than 5 times a week
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome of disease severity based on Psoriasis Area Severity Index (PASI). Timepoint: The measurement of the primary outcome variable is based on time intervals 0, and in weeks 4, 8, and 12 after the start of the intervention. Method of measurement: The primary outcome variable is evaluated using the Psoriasis Area Severity Index criterion, which ranges from 0 to 72. The effectiveness of the treatment is in the form of changes in the PASI criterion from baseline to the last week. A complete response is when the PASI standard decreases to zero in the last week, a marked response is when the PASI standard is reduced by more than 75% from the baseline, a moderate response is when the standard PASI should decrease between 50 and 74%; A slight response is when the PASI score decreases by less than 50%. No response is when the lesions do not change during twelve weeks of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome is that at the beginning of visiting the clinic and entering the study, and at the end of the twelfth week, a photo of the lesions is taken, and the degree of improvement in the lesions is scored from zero to ten through a visual analog scale. (zero for lesions that have not improved at all and ten for the best response to treatment). Timepoint: At the beginning of the study and at the end of the twelfth week after the start of the intervention, the secondary outcome is evaluated. Method of measurement: The rate of recovery in the process of lesions through visual analog scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGolnaz Afzal
Yazd University of Medical Sciences
Outcome results
None listed